OSCP1

Summary

OSCP1 (organic solute carrier partner 1, HGNC:29971) is a protein-coding gene on chromosome 1p34.3, encoding Protein OSCP1 (Q8WVF1). May be involved in drug clearance in the placenta.

Enables transmembrane transporter activity. Involved in xenobiotic detoxification by transmembrane export across the plasma membrane. Located in basal plasma membrane and cytoplasm.

Source: NCBI Gene 127700 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 58 total
• MANE Select transcript: NM_145047

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29971
Approved symbol	OSCP1
Name	organic solute carrier partner 1
Location	1p34.3
Locus type	gene with protein product
Status	Approved
Aliases	NOR1
Ensembl gene	ENSG00000116885
Ensembl biotype	protein_coding
OMIM	608854
Entrez	127700

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 8 protein_coding, 3 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000235532, ENST00000354267, ENST00000356637, ENST00000433045, ENST00000445843, ENST00000468441, ENST00000471369, ENST00000475160, ENST00000495222, ENST00000524789, ENST00000525869, ENST00000528112, ENST00000955706, ENST00000955707

RefSeq mRNA: 3 — MANE Select: NM_145047 NM_001330493, NM_145047, NM_206837

CCDS: CCDS409, CCDS410, CCDS81301

Canonical transcript exons

ENST00000235532 — 10 exons

Exon	Start	End
ENSE00001323342	36450258	36450451
ENSE00002178989	36420476	36420615
ENSE00003465921	36432422	36432589
ENSE00003483662	36423363	36423466
ENSE00003510162	36418991	36419054
ENSE00003555983	36438756	36438910
ENSE00003593920	36417906	36418255
ENSE00003599627	36422150	36422219
ENSE00003605733	36431802	36431882
ENSE00003662546	36422768	36422896

Expression profiles

Bgee: expression breadth ubiquitous, 140 present calls, max score 97.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.4190 / max 133.9722, expressed in 1483 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
11731	3.6487	1401
11732	0.4623	205
11730	0.3036	146
11729	0.0045	1

Top tissues by expression

143 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	97.19	gold quality
left testis	UBERON:0004533	96.36	gold quality
right testis	UBERON:0004534	96.08	gold quality
testis	UBERON:0000473	95.87	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.20	gold quality
pituitary gland	UBERON:0000007	92.89	gold quality
adenohypophysis	UBERON:0002196	92.51	gold quality
fallopian tube	UBERON:0003889	90.00	gold quality
nucleus accumbens	UBERON:0001882	89.64	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.16	gold quality
caudate nucleus	UBERON:0001873	88.97	gold quality
hypothalamus	UBERON:0001898	88.48	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.11	gold quality
superior frontal gyrus	UBERON:0002661	87.98	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	87.67	gold quality
left lobe of thyroid gland	UBERON:0001120	87.46	gold quality
thyroid gland	UBERON:0002046	87.37	gold quality
right frontal lobe	UBERON:0002810	87.29	gold quality
frontal cortex	UBERON:0001870	87.26	gold quality
prefrontal cortex	UBERON:0000451	87.23	gold quality
right lobe of thyroid gland	UBERON:0001119	87.13	gold quality
cerebral cortex	UBERON:0000956	86.92	gold quality
primary visual cortex	UBERON:0002436	86.89	gold quality
putamen	UBERON:0001874	86.86	gold quality
brain	UBERON:0000955	86.83	gold quality
calcaneal tendon	UBERON:0003701	86.16	gold quality
Ammon’s horn	UBERON:0001954	86.02	gold quality
anterior cingulate cortex	UBERON:0009835	85.92	gold quality
ventricular zone	UBERON:0003053	85.70	gold quality
adult mammalian kidney	UBERON:0000082	85.56	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	10.95
E-MTAB-9388	yes	8.07
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

27 targeting OSCP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-4524A-5P	99.57	71.73	1193
HSA-MIR-4524B-5P	99.57	71.68	1195
HSA-MIR-936	98.87	70.51	1124
HSA-MIR-4297	98.77	66.95	2013
HSA-MIR-653-3P	98.31	67.71	1542
HSA-MIR-1271-3P	97.56	64.85	865
HSA-MIR-550A-3-5P	97.56	65.35	823
HSA-MIR-550A-5P	97.56	65.35	823
HSA-MIR-550B-2-5P	96.56	64.61	646
HSA-MIR-4268	94.45	64.09	819

Literature-anchored findings (GeneRIF, showing 8)

• We cloned a novel gene NOR(1), and the Glu58Gly polymorphism of NOR(1) may be involved in the development and/or progression of NPC suggesting that NOR(1) could be a candidate tumor repressor gene related with NPC. (PMID:12819961)
• hOSCP1 is a novel polyspecific organic solute carrier protein responsible for drug clearance from the human placenta (PMID:16006562)
• NOR(1) gene may have some effects on liver cancer by up-regulating the expression of these proteins. (PMID:18237537)
• NOR1 protein is predominantly expressed in human nasopharynx and tracheal tissues and is frequently down-expressed in NPC. (PMID:19727524)
• Frequent epigenetic inactivation of the NOR1 gene in nasopharyngeal carcinoma (NPC) suggests that it may be a critical tumor suppressor involved in the development of nasopharyngeal carcinoma. (PMID:21803736)
• Data revealed novel aspects of the interplay between autophagy and apoptosis in nasopharyngeal carcinoma cells, which underlies the tumor suppression function of NOR1. (PMID:23831407)
• Results identified NOR1 as a downstream target gene of miR-199a which is critical for regulating cell proliferation and migration by targeting and upregulating NOR1 in human HepG2 cells. (PMID:26781989)
• Abberant expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma. (PMID:29227538)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	OSCP1	ENSDARG00000101888
danio_rerio	oscp1a	ENSDARG00000104403
mus_musculus	Oscp1	ENSMUSG00000042616
rattus_norvegicus	Oscp1	ENSRNOG00000026978
drosophila_melanogaster	OSCP1	FBGN0033685
caenorhabditis_elegans		WBGENE00019996

Protein

Protein identifiers

Protein OSCP1 — Q8WVF1 (reviewed: Q8WVF1)

Alternative names: Organic solute transport protein 1, Oxidored-nitro domain-containing protein 1

All UniProt accessions (5): C9JF58, Q8WVF1, H0YAG0, H0YDT3, H7C0S2

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in drug clearance in the placenta.

Subcellular location. Basal cell membrane.

Tissue specificity. Expressed predominantly in testis, also found in placenta and to a lesser extent in thymus and small intestine; abundantly expressed in tumor-derived cell lines. Ubiquitously expressed.

Miscellaneous. May be involved in the development and/or progression of nosopharyngeal carcinoma.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8WVF1-1	1	yes
Q8WVF1-2	2
Q8WVF1-3	3
Q8WVF1-4	4

RefSeq proteins (3): NP_001317422, NP_659484, NP_996668 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019332	OSCP1	Family

Pfam: PF10188

UniProt features (11 total): splice variant 4, sequence conflict 3, sequence variant 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WVF1-F1	77.95	0.52

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 56 (showing top): SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, chr1p34, GOBP_DETOXIFICATION, GOBP_RESPONSE_TO_TOXIC_SUBSTANCE, CUI_TCF21_TARGETS_2_UP, GOBP_TRANSMEMBRANE_TRANSPORT, MARSON_BOUND_BY_E2F4_UNSTIMULATED, GOCC_PLASMA_MEMBRANE_REGION, GOCC_BASAL_PART_OF_CELL, DODD_NASOPHARYNGEAL_CARCINOMA_DN, GOMF_TRANSPORTER_ACTIVITY, STAMBOLSKY_RESPONSE_TO_VITAMIN_D3_UP, CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_DN, LINSLEY_MIR16_TARGETS, GOBP_XENOBIOTIC_TRANSPORT

GO Biological Process (1): xenobiotic detoxification by transmembrane export across the plasma membrane (GO:1990961)

GO Molecular Function (1): transmembrane transporter activity (GO:0022857)

GO Cellular Component (4): cytoplasm (GO:0005737), plasma membrane (GO:0005886), basal plasma membrane (GO:0009925), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
xenobiotic export from cell	1
detoxification	1
export across plasma membrane	1
transporter activity	1
transmembrane transport	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
basal part of cell	1
plasma membrane region	1

Protein interactions and networks

STRING

384 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OSCP1	MRPS15	P82914	490
OSCP1	ARL14EP	Q8N8R7	466
OSCP1	NPM2	Q86SE8	448
OSCP1	STK40	Q8N2I9	432
OSCP1	LIX1L	Q8IVB5	403
OSCP1	STS	P08842	402
OSCP1	PSMD3	O43242	396
OSCP1	PDLIM4	P50479	349
OSCP1	CAGE1	Q8TC20	349
OSCP1	GON7	Q9BXV9	342
OSCP1	CSF3R	Q99062	332
OSCP1	FSIP2	Q5CZC0	319
OSCP1	SEC22C	Q9BRL7	318
OSCP1	G3V325	G3V325	315
OSCP1	CBLL2	Q8N7E2	305
OSCP1	CCDC157	Q569K6	305

IntAct

14 interactions, top by confidence:

A	B	Type	Score
GYG2	GYS1	psi-mi:“MI:0914”(association)	0.660
KANK4	TRAPPC3	psi-mi:“MI:0914”(association)	0.640
MPDZ	SMCHD1	psi-mi:“MI:0914”(association)	0.590
NFATC2IP	ZNHIT1	psi-mi:“MI:0914”(association)	0.530
USP16	HERC2	psi-mi:“MI:0914”(association)	0.530
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
FST	ZZEF1	psi-mi:“MI:0914”(association)	0.350
DEFB125	ZZEF1	psi-mi:“MI:0914”(association)	0.350
IKZF4	OBSL1	psi-mi:“MI:0914”(association)	0.350
GYG2	UBB	psi-mi:“MI:0914”(association)	0.350
DRG1	ACTA2	psi-mi:“MI:0914”(association)	0.350
WDR54	OSCP1	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-RNA), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS)

ESM2 similar proteins: A4IG66, A8E4M4, A9JSQ8, B0BN72, B2RYF7, C9JLW8, E1C760, E7EXT2, F1RCE7, F7AEX0, P97578, Q02225, Q0P4B9, Q0VBD2, Q28DG6, Q28E45, Q29S00, Q32LE2, Q3MHI4, Q3UGS4, Q4QQS3, Q4V8E4, Q5BLE2, Q5EAW4, Q5M8L3, Q5R789, Q5RHY1, Q5VSY0, Q5XIG5, Q5ZIU1, Q5ZKA6, Q6DD45, Q6GNQ4, Q6GR21, Q6IEG0, Q6NRB7, Q6NWC9, Q6NZY4, Q6TYB5, Q7L590

Diamond homologs: Q29S00, Q4QQS3, Q8BHW2, Q8WVF1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	44
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1822 predictions. Top by Δscore:

Variant	Effect	Δscore
1:36418986:CGTA:C	donor_loss	1.0000
1:36418987:GTA:G	donor_loss	1.0000
1:36418988:TA:T	donor_loss	1.0000
1:36419064:A:AC	acceptor_gain	1.0000
1:36419064:A:C	acceptor_gain	1.0000
1:36420474:A:AC	donor_gain	1.0000
1:36420474:ACT:A	donor_gain	1.0000
1:36420475:C:CC	donor_gain	1.0000
1:36420475:CTC:C	donor_gain	1.0000
1:36420475:CTCCT:C	donor_gain	1.0000
1:36420477:C:CA	donor_gain	1.0000
1:36422766:A:AC	donor_gain	1.0000
1:36422767:C:CC	donor_gain	1.0000
1:36422893:CATT:C	acceptor_gain	1.0000
1:36422895:TT:T	acceptor_gain	1.0000
1:36422897:C:CC	acceptor_gain	1.0000
1:36423465:ACC:A	acceptor_loss	1.0000
1:36423467:CTG:C	acceptor_loss	1.0000
1:36423468:T:A	acceptor_loss	1.0000
1:36431800:A:AC	donor_gain	1.0000
1:36431801:C:CC	donor_gain	1.0000
1:36431801:CT:C	donor_gain	1.0000
1:36432416:TCTTA:T	donor_loss	1.0000
1:36432417:CTTA:C	donor_loss	1.0000
1:36432418:TTAC:T	donor_loss	1.0000
1:36432419:TACTT:T	donor_loss	1.0000
1:36432420:A:AC	donor_gain	1.0000
1:36432420:A:C	donor_loss	1.0000
1:36432421:C:CC	donor_gain	1.0000
1:36432421:CTT:C	donor_gain	1.0000

AlphaMissense

2490 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:36432579:A:G	L103P	0.997
1:36438765:G:C	S96R	0.997
1:36438765:G:T	S96R	0.997
1:36438767:T:G	S96R	0.997
1:36432588:A:G	L100P	0.996
1:36431842:C:G	R169P	0.995
1:36432560:T:A	K109N	0.995
1:36432560:T:G	K109N	0.995
1:36450296:A:G	L25P	0.995
1:36438799:G:T	A85D	0.994
1:36450299:C:G	R24P	0.994
1:36450308:A:G	L21P	0.994
1:36423437:C:A	Q192H	0.993
1:36423437:C:G	Q192H	0.993
1:36432561:T:A	K109I	0.993
1:36431833:A:G	L172P	0.992
1:36438778:A:G	L92P	0.992
1:36438802:A:G	L84P	0.992
1:36438778:A:T	L92Q	0.991
1:36432505:G:C	H128D	0.990
1:36432562:T:C	K109E	0.990
1:36432588:A:T	L100H	0.990
1:36438823:A:G	L77P	0.990
1:36450334:G:C	N12K	0.990
1:36450334:G:T	N12K	0.990
1:36422778:C:G	G257R	0.989
1:36422778:C:T	G257R	0.989
1:36450330:C:G	G14R	0.989
1:36432429:A:G	L153P	0.988
1:36422777:C:T	G257E	0.987

dbSNP variants (sampled 300 via entrez): RS1000173207 (1:36430862 C>T), RS1000243669 (1:36441636 C>T), RS1000482534 (1:36428482 A>T), RS1000493470 (1:36427596 C>T), RS1000544856 (1:36421089 T>C), RS1000598151 (1:36428055 C>T), RS1000831288 (1:36421473 C>T), RS1000844668 (1:36441815 G>A,T), RS1001068232 (1:36448777 G>A), RS1001076529 (1:36434826 T>C), RS1001225049 (1:36446387 T>A), RS1001228640 (1:36429778 A>C), RS1001293491 (1:36440972 C>G), RS1001297117 (1:36446189 A>T), RS1001318775 (1:36449157 C>A,G)

Disease associations

OMIM: gene MIM:608854 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001017_4	Diabetic retinopathy	4.000000e-06
GCST005974_10	Neutrophil count	4.000000e-16
GCST007007_1	Cerebrospinal fluid t-tau levels	2.000000e-06
GCST007008_1	Cerebrospinal fluid p-tau levels	5.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0004760	t-tau measurement
EFO:0004763	p-tau measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	increases methylation, affects cotreatment	1
trichostatin A	decreases expression	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	decreases methylation	1
pentanal	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	affects cotreatment, decreases methylation	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation, decreases methylation	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects methylation	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Carbamazepine	affects expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methapyrilene	decreases methylation	1
Methyl Methanesulfonate	increases expression	1
Smoke	increases abundance, increases expression	1
Dronabinol	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.